WASHINGTON: Patients battling advanced breast cancer have gained another treatment option after the US Food and Drug Administration (FDA) approved a new oral medicine developed by Swiss pharmaceutical company Roche, following clinical trial results showing that it could help delay the worsening of the disease.
The medicine, called Wilserdly (giredestrant), received FDA approval on November 16, 2026, for use alongside an existing cancer medicine, everolimus, in certain adults whose breast cancer has continued to grow or returned despite earlier hormone-based treatment.
The approval offers an additional treatment option for patients facing a difficult stage of breast cancer, particularly when previously effective medicines are no longer able to control the disease.
In a major clinical trial, patients receiving the new treatment alongside everolimus went a median of 10 months before their cancer worsened or they died, compared with 5.5 months among those receiving another hormone treatment with everolimus.
Researchers also found that the new treatment reduced the relative risk of cancer progression or death by 62% during the study, suggesting that it could help eligible patients gain additional months of disease control.
Although the findings are encouraging, the medicine is not a cure, and its approval is limited to a particular type of advanced breast cancer.
The development is especially important because breast cancer can become increasingly difficult to treat when it spreads beyond the breast or stops responding to medicines that previously kept it under control.
Many breast cancers depend on the hormone estrogen to grow. Doctors commonly prescribe treatments that block the hormone's effects, helping slow the disease. However, some tumours eventually develop changes that allow cancer cells to continue growing despite these medicines.
Roche's newly approved treatment is designed to address one such form of resistance.
Wilserdly works by breaking down receptors through which estrogen encourages the growth of certain breast cancer cells. Everolimus, the medicine prescribed alongside it, blocks a different process involved in cancer growth.
By targeting the disease in two ways, the treatment aims to maintain cancer control even after earlier hormone therapies have become less effective.
Both medicines are taken by mouth, providing an oral treatment option without the need for injections or infusions to administer these two drugs. Patients must nevertheless remain under medical supervision to assess their response and monitor possible side effects.
The FDA's decision was supported by results from an international clinical trial involving 373 adults with advanced breast cancer. Among them, 207 had a particular genetic change known as an ESR1 mutation, which can make some breast cancers resistant to conventional hormone treatments.
It was among these patients that the new treatment demonstrated a significant benefit, with the median period before disease progression or death extending to 10 months, compared with 5.5 months in the comparison group.
The reported 62% reduction relates to the combined risk of cancer progression or death during the trial. It does not mean that 62% of patients were cured or that the medicine reduced cancer deaths by the same percentage.
Whether the treatment helps patients live longer overall remains uncertain, as longer-term survival results were not yet sufficiently developed when the FDA reviewed the findings.
The trial results were published in The New England Journal of Medicine, providing scientific evidence supporting the approval.
Despite its encouraging results, Wilserdly is not intended for everyone diagnosed with breast cancer.
The FDA has approved it for adults with certain advanced or metastatic breast cancers that are influenced by estrogen, do not have excess levels of a protein called HER2, and carry the ESR1 genetic mutation.
Patients must also meet the approval's requirements concerning previous hormone-based treatment and subsequent worsening or recurrence of their cancer.
Doctors can use an authorised genetic test to identify whether a patient's tumour carries the mutation needed to qualify for the medicine.
This approach reflects a growing change in cancer care, where treatment decisions increasingly depend on the biological characteristics of a patient's tumour rather than the cancer diagnosis alone.
Dr Erica L. Mayer, Director of Breast Cancer Clinical Research at the Dana-Farber Cancer Institute in the United States, said in a statement released by Roche that patients whose advanced breast cancer progresses despite hormone treatment often face increasingly difficult treatment decisions. She highlighted the potential of the new oral treatment to provide longer disease control for patients with the relevant genetic change.
While the approval represents another advance in breast cancer treatment, Wilserdly is not the first oral medicine developed for the disease.
Other oral treatments have been available for years, including newer medicines such as Orserdu, approved by the FDA in 2023, and Eli Lilly's Inluriyo, which received US approval in 2025 for certain patients with advanced breast cancer.
The significance of Roche's medicine lies in adding another treatment option supported by clinical evidence for patients whose disease has become resistant to earlier therapy.
However, like other cancer medicines, Wilserdly carries potential risks that must be considered alongside its benefits.
The FDA-approved prescribing information includes warnings about an unusually slow heart rate and possible harm to an unborn baby. Patients receiving the treatment alongside everolimus may also experience mouth sores, fatigue, diarrhoea, nausea, skin rashes and other complications.
The treatment can also affect blood counts and certain laboratory test results, making regular assessment by a cancer specialist important.
Affordability may present another challenge.
Roche told Reuters that Wilserdly will be priced at approximately $22,500 per month in the United States, placing it among expensive modern cancer treatments.
The reported price applies to Wilserdly itself and does not necessarily include the cost of everolimus, medical consultations, laboratory investigations or other treatment-related expenses.
The company expects the medicine to become available in the United States in the coming weeks.
For patients in Pakistan and other countries, however, FDA approval does not automatically mean the medicine will become locally available. Access will depend on national regulatory approvals, commercial availability and pricing arrangements.
Meanwhile, Roche is seeking to expand the use of Wilserdly beyond advanced breast cancer.
The company has submitted a separate application to the FDA seeking approval for the medicine as a treatment after initial care for certain patients with early-stage breast cancer who face a risk of the disease returning.
The US regulator is expected to announce its decision on that application by November 30, 2026.
If approved, the medicine could offer another treatment option at an earlier stage of the disease. However, that use remains under review and is not covered by the latest approval.
For now, the FDA's decision represents an additional step in the development of more targeted treatments for advanced breast cancer.
Although it does not promise a cure, the new oral medicine offers eligible patients another opportunity to keep the disease under control for longer, particularly when earlier treatments have stopped working.
For patients and families navigating the challenges of advanced cancer, the development highlights how continuing medical research is gradually expanding the options available to manage a disease that remains difficult to treat.
CLICK HERE TO FOLLOW Medical News Pakistan's official WhatsApp channel for new cancer medicines, clinical trials and regulatory approvals continue to shape treatment options worldwide.